Clinical Trials
130 trialsOPTICAL-3
Sun Yat-sen University
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
West China Hospital
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Chase
Fudan University
INS-ESCC-CT
Sichuan University
TORCH-iTNT
Fudan University
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
PRISM-TNBC
Shandong Cancer Hospital and Institute
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
SKY
Sichuan University
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
RICE
Shanghai Chest Hospital
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Lalo
Eastern Hepatobiliary Surgery Hospital
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
ILDR-03
Shantou University Medical College
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Anhui Provincial Hospital
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
Jinan Military General Hospital
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MODIFI-CC
Sixth Affiliated Hospital, Sun Yat-sen University
MODIFI-L
Sixth Affiliated Hospital, Sun Yat-sen University
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRIMM
University Medical Centre Maribor
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
Jinling Hospital, China
RAD-VACCINE
The Methodist Hospital Research Institute
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
BioAtla, Inc.
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
DECIDING
RenJi Hospital
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
PTCA199-8
Fudan University
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
Xinqiao Hospital of Chongqing
PLATINUM
Sun Yat-sen University
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
Tongji Hospital
STELLARIII
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ILDR-01
Shantou University Medical College
PROPHET
Sun Yat-sen University